Literature DB >> 1276589

Late effects of x irradiation in patients treated for metropathia haemorrhagica.

P G Smith, R Doll.   

Abstract

We have previously reported on the causes of death among 2,068 patients treated with X irradiation for metropathia haemorrhagica at three Scottish radiotherapy centres between 1940 and 1960 (Doll and Smith, 1968). This cohort of women has now been followed up for a further seven years. 500 (24 per cent) women have now died, 78 (3-8 per cent) have emigrated and 25 (1-2 per cent) could not be traced. The numbers of deaths from different causes have been compared with the numbers expected in a population of similar age and sex exposed to the Scottish national mortality rates over the same period. An excess of deaths from leukaemia (seven observed, 2-3 expected) and of cancers of the heavily irradiated sites (59 observed, 40-1 expected) continues to be observed five or more years after treatment. There is no indication of any change in the excess death rate, due to cancers of sites in the radiation field, with time since treatment up to at least 20 years after the radiation exposure. Over the same period the number of deaths from cancer of the breast was below expectation (ten observed, 22-3 expected) and no increased mortality from coronary disease was seen (102 observed, 100-9 expected). The mean dose of radiation to the bone marrow has been determined for each woman ant it is estimated that the excess rate of leukaemia in the first 20 years after treatment is about 1-1 per million women per year per rad. This figure is in accord with the estimates derived from the survivors of the atomic bomb explosions in Hiroshima and Nagasaki and among patients with ankylosing spondylitis treated with X irradiation. However, the finding of no excess risk of leukemia among women treated with irradiation for cancer of the cervix (Hutchison, 1968) suggests that the simple assumption of a linear dose-response relationship for leukaemia is incorrect, at least when high doses of radiation are delivered to a small volume of marrow.

Entities:  

Mesh:

Year:  1976        PMID: 1276589     DOI: 10.1259/0007-1285-49-579-224

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  16 in total

Review 1.  Cardiac side effects of conventional and particle radiotherapy in cancer patients.

Authors:  A Wittig; R Engenhart-Cabillic
Journal:  Herz       Date:  2011-06       Impact factor: 1.443

2.  A second brain tumour and irradiation.

Authors:  R G Robinson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1978-11       Impact factor: 10.154

3.  Comments on "background stratified poisson regression analysis of cohort data" by Richardson and Langholz, Radiat Environ Biophys 51(1): 15-22.

Authors:  Colin R Muirhead; Richard G E Haylock
Journal:  Radiat Environ Biophys       Date:  2012-09-23       Impact factor: 1.925

4.  Synchronous small and large bowel cancer developing after pelvic irradiation.

Authors:  H Gajraj; D R Davies; B T Jackson
Journal:  Gut       Date:  1988-01       Impact factor: 23.059

Review 5.  Carcinogenic risk in diagnostic nuclear medicine: biological and epidemiological considerations.

Authors:  F Overbeek; E K Pauwels; J J Broerse
Journal:  Eur J Nucl Med       Date:  1994-09

Review 6.  Identifying the health risks from very low-dose sparsely ionizing radiation.

Authors:  N A Dreyer; E Friedlander
Journal:  Am J Public Health       Date:  1982-06       Impact factor: 9.308

Review 7.  [Radiation reactions in the gonads: importance in patient counseling].

Authors:  T Herrmann
Journal:  Strahlenther Onkol       Date:  1997-10       Impact factor: 3.621

8.  Postoperative radiotherapy and late mortality: evidence from the Cancer Research Campaign trial for early breast cancer.

Authors:  J L Haybittle; D Brinkley; J Houghton; R P A'Hern; M Baum
Journal:  BMJ       Date:  1989-06-17

Review 9.  Pelvic radiotherapy, sex hormones, and breast cancer.

Authors:  P D Inskip
Journal:  Cancer Causes Control       Date:  1994-09       Impact factor: 2.506

10.  Second primary cancer following treatment for cervical cancer.

Authors:  E A Clarke; N Kreiger; R F Spengler
Journal:  Can Med Assoc J       Date:  1984-09-15       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.